Longeveron

LGVNPhase 2

Miami, United StatesFounded 2014longeveron.com

Longeveron is focused on developing safe and effective 'off-the-shelf' cellular therapies to repair, regenerate, and restore tissue, with the core mission of improving healthspan—the period of life lived in good health. Founded in 2014, the company has generated positive clinical data across five trials in three core indications and has secured over $16 million in grant funding from prestigious organizations like the NIH and Alzheimer's Association. With a state-of-the-art manufacturing facility in Miami, Longeveron is advancing its lead candidate, Lomecel-B™, toward pivotal trials in Alzheimer's disease and Hypoplastic Left Heart Syndrome (HLHS).

Market Cap

$1.1B

Founded

2014

Focus

Cell & Gene Therapy

LGVN · Stock Price

USD 39.2534.85 (-47.03%)

Historical price data

AI Company Overview

Technology Platform

Platform based on culture-expanded, allogeneic mesenchymal stem cells (MSCs) sourced from young adult donor bone marrow, designed to exert therapeutic effects through multiple mechanisms of action including tissue repair, immunomodulation, and angiogenesis.

Pipeline Snapshot

10 drugs in pipeline

Drug	Indication	Stage
Peripheral Intravenous (IV) infusion of LMSCs	Metabolic Disease	Phase 2
Longeveron Mesenchymal Stem Cells (LMSCs)	Aging Frailty	Phase 2
Lomecel-B medicinal signaling cells	Hypoplastic Left Heart Syndrome	Phase 2
Allogeneic MSC	Mild Alzheimer's Disease	Phase 2
Longeveron Mesenchymal Stem Cells (LMSCs) + Fluzone High Dose Vaccine	Aging Frailty	Phase 1/2

Opportunities

Longeveron has significant opportunities in the vast, underserved markets of aging-related decline and rare pediatric heart disease.

Success in its ongoing Phase 2b Alzheimer's trial (ELPIS II) could unlock major partnership deals or enhance its valuation.

The company's in-house GMP manufacturing also provides a potential revenue stream through CDMO services and a strategic asset for scaling.

Risk Factors

Key risks include clinical trial failures, particularly for the capital-intensive Alzheimer's program, the need for additional dilutive financing given its pre-revenue status, and the complex regulatory and manufacturing challenges inherent in cell therapy development.

Competition in neurodegenerative diseases is intense.

Competitive Landscape

Longeveron competes in the mesenchymal stem cell (MSC) therapy space and faces competition from other biotechs in aging/frailty and Alzheimer's disease. Its differentiation lies in its specific multi-mechanism approach to healthspan, proprietary manufacturing, and first-mover advantage in clinical-stage cell therapy for HLHS, a rare disease with minimal competition.